Manufacturing & Portfolio

Developing the standard in peptide manufacturing

Vector Science & Therapeutics provides cGMP-manufactured Rx peptides made using pharma-grade Active Pharmaceutical Ingredients (APIs) and uses only 3rd-party testing that is validated for each peptide, along with stability studies, to supply the orthopedic, sports medicine, and regenerative medicine channels with a verified chain of control and direct-to-physician supply.

Now in Production cGMP Manufacturing Direct to Physician Only
Our Business Model

Manufacturing,
Not Dispensing

Vector's peptide business is a manufacturing and supply model: we produce peptides for physicians and their patients across sports, regenerative, and longevity medicine channels.

Every batch is manufactured cGMP, using pharma-grade APIs, in a US-based, FDA-licensed contract development and manufacturing organization (CDMO) facility, with an accompanying certificate of analysis for every lot. Quality and analytical testing (purity, potency, and consistency) is performed by Verlytix, an FDA-licensed 3rd-party analytical lab.

Vector does not dispense peptides directly to patients. We are direct to physician only.

cGMP Manufacturing

Produced in a US-based, FDA-licensed CDMO facility.

Verified Quality

3rd-party certificate of analysis on every lot, with testing validated for each peptide.

Scaling Capacity

First of four cGMP suites came online in August 2026.

Direct to Physician

Direct to physician only, never dispensed directly to patients.

cGMP peptide manufacturing cleanroom with a stainless-steel process line and an open lyophilizer holding shelves of vials
Manufacturing Capacity

Built for Scale.
Setting the Standard.

The first of four cGMP suites at LyoGenesisPlus Manufacturing came online in August 2026, with a 3rd-party certificate of analysis on every lot. Depending on demand, management estimates up to 800,000 vials per month at full capacity.

cGMP
FDA-Licensed CDMO Facility
100%
Lots With CoA
800K
Monthly Vial Capacity
Our Manufacturing Standard

One Discipline, Applied Everywhere

Peptide quality and supply are governed by the same discipline Vector applies across every part of the business, with specific focus on rigorous process control, verified output, and a supply chain built to last.

01 · Control

Process Control

cGMP manufacturing processes and quality protocols informed by rigorous process controls at every stage of production, not one-size batch production.

02 · Distribution

Verified Chain of Control

A verified chain of control from cGMP production to the physician, supplying orthopedic, sports, and regenerative medicine practices direct to physician only — never general consumer sale.

03 · Capacity

Durable Capacity

Manufacturing capacity and quality infrastructure built to scale sustainably, supporting long-term supply relationships rather than one-off production runs.

Distributor Network

Where Our Distributor Network Is Focused

Vector is building a dedicated distributor network to support the peptide portfolio across three channels.

Orthopedic

Supporting musculoskeletal and joint-focused practices managing degenerative joint disease and soft tissue injury, including osteoarthritis.

0M+
Americans affected by osteoarthritis

Sports Medicine

Supporting high-performance clinical environments where soft tissue injury and recovery timelines drive practice decision-making.

Regenerative Medicine

Supporting practices focused on tissue-level intervention and recovery, consistent with Vector's broader musculoskeletal regeneration mission.

Quality Infrastructure

Verified at Every Step

From cGMP production processes to 3rd-party release testing, each lot follows a verified chain of control before it reaches the physician.

cGMP Production Processes
LyoGenesisPlus Manufacturing
3rd-Party Testing
Verlytix
Certificate of Analysis
Every Lot
Quality Release
Purity · Potency · Consistency
Physician
Direct to Physician Only
HPLC autosampler needle positioned above rows of sample vials in an analytical testing laboratory
Quality & Analytical Testing

Verlytix

Vector uses Verlytix for its 3rd-party analytical testing. Verlytix is an independent, FDA-licensed analytical lab that performs release testing validated for each peptide (sterility, purity, potency, endotoxin levels, and water content) along with stability studies, independently verifying consistency across the peptide portfolio.

Sterility Purity Potency Endotoxins Water Content Independent CoA
Rows of lyophilized peptide vials with grey stoppers on a frosted lyophilizer shelf
Manufacturing & Lyophilization

LyoGenesisPlus Manufacturing

LyoGenesisPlus Manufacturing provides the manufacturing and lyophilization expertise behind Vector's peptide production, operating under cGMP, FDA, and ISO qualification standards — including Class 5 cleanroom validation, calibrated equipment, and documented SOPs.

cGMP FDA ISO Class 5 Cleanroom Documented SOPs
Learn About Verlytix Manufacturing Update
On Site

Inside the Facility

Laboratory and analytical space supporting Vector's peptide program, photographed on site.

Analytical laboratory at a Vector facility with chromatography instrumentation on the bench
Analytical Laboratory
Chromatography instrumentation for purity, potency, and consistency testing
Laboratory suite at a Vector facility with a fume hood, benchwork, and instrumentation
Laboratory Suite
Fume hood and benchwork supporting formulation and quality workflows

Photographs of Vector facilities. The first of four cGMP manufacturing suites came online in August 2026.

Regulatory & Development Status

Rx Products — Physician Use Only

Vector sells Rx-labeled peptide products for physician use only.

In October 2026, The Washington Post reported that the US administration is developing a plan to allow restricted peptides to be sold through compounding pharmacies, reportedly including BPC-157 and other peptides that Vector produces under its rigorous cGMP process. The plan has not been finalized.

Vector's peptide portfolio is in early commercial manufacturing: the first of four cGMP suites came online in August 2026, and full four-suite capacity of up to 800,000 vials per month is a management estimate that depends on demand, as disclosed in Vector's press releases of July 7 and August 24, 2026. Product-level specifications and indicated uses are not publicly disclosed and are subject to change as production, regulatory guidance, and distribution agreements evolve.

Request a Credentialed Briefing

Detailed portfolio specifications, supply arrangements, and distribution terms are available to qualified distributors, clinical partners, and institutional investors under appropriate engagement.

Request a Briefing Investor Relations